These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 21256218)

  • 1. Dual functional RNA nanoparticles containing phi29 motor pRNA and anti-gp120 aptamer for cell-type specific delivery and HIV-1 inhibition.
    Zhou J; Shu Y; Guo P; Smith DD; Rossi JJ
    Methods; 2011 Jun; 54(2):284-94. PubMed ID: 21256218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of cell-type specific anti-HIV gp120 aptamers for siRNA delivery.
    Zhou J; Li H; Zhang J; Piotr S; Rossi J
    J Vis Exp; 2011 Jun; (52):. PubMed ID: 21730942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy.
    Zhou J; Li H; Li S; Zaia J; Rossi JJ
    Mol Ther; 2008 Aug; 16(8):1481-9. PubMed ID: 18461053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cells.
    Zhou J; Swiderski P; Li H; Zhang J; Neff CP; Akkina R; Rossi JJ
    Nucleic Acids Res; 2009 May; 37(9):3094-109. PubMed ID: 19304999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aptamer-targeted RNAi for HIV-1 therapy.
    Zhou J; Rossi JJ
    Methods Mol Biol; 2011; 721():355-71. PubMed ID: 21431697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Receptor-targeted aptamer-siRNA conjugate-directed transcriptional regulation of HIV-1.
    Zhou J; Lazar D; Li H; Xia X; Satheesan S; Charlins P; O'Mealy D; Akkina R; Saayman S; Weinberg MS; Rossi JJ; Morris KV
    Theranostics; 2018; 8(6):1575-1590. PubMed ID: 29556342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bottom-up assembly of RNA nanoparticles containing phi29 motor pRNA to silence the asthma STAT5b gene.
    Qiu C; Peng WK; Shi F; Zhang T
    Genet Mol Res; 2012 Sep; 11(3):3236-45. PubMed ID: 23079817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assembly of multifunctional phi29 pRNA nanoparticles for specific delivery of siRNA and other therapeutics to targeted cells.
    Shu Y; Cinier M; Shu D; Guo P
    Methods; 2011 Jun; 54(2):204-14. PubMed ID: 21320601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of specific delivery of chimeric phi29 pRNA/siRNA nanoparticles to multiple tumor cells.
    Li L; Liu J; Diao Z; Shu D; Guo P; Shen G
    Mol Biosyst; 2009 Nov; 5(11):1361-8. PubMed ID: 19823753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional in vivo delivery of multiplexed anti-HIV-1 siRNAs via a chemically synthesized aptamer with a sticky bridge.
    Zhou J; Neff CP; Swiderski P; Li H; Smith DD; Aboellail T; Remling-Mulder L; Akkina R; Rossi JJ
    Mol Ther; 2013 Jan; 21(1):192-200. PubMed ID: 23164935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Specific delivery of therapeutic RNAs to cancer cells via the dimerization mechanism of phi29 motor pRNA.
    Guo S; Tschammer N; Mohammed S; Guo P
    Hum Gene Ther; 2005 Sep; 16(9):1097-109. PubMed ID: 16149908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluorogenic RNA nanoparticles for monitoring RNA folding and degradation in real time in living cells.
    Reif R; Haque F; Guo P
    Nucleic Acid Ther; 2012 Dec; 22(6):428-37. PubMed ID: 23113765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aptamer-siRNA chimeras for HIV.
    Takahashi M; Burnett JC; Rossi JJ
    Adv Exp Med Biol; 2015; 848():211-34. PubMed ID: 25757623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Construction of folate-conjugated pRNA of bacteriophage phi29 DNA packaging motor for delivery of chimeric siRNA to nasopharyngeal carcinoma cells.
    Guo S; Huang F; Guo P
    Gene Ther; 2006 May; 13(10):814-20. PubMed ID: 16482206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Application of phi29 motor pRNA for targeted therapeutic delivery of siRNA silencing metallothionein-IIA and survivin in ovarian cancers.
    Tarapore P; Shu Y; Guo P; Ho SM
    Mol Ther; 2011 Feb; 19(2):386-94. PubMed ID: 21063391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. UCLA1, a synthetic derivative of a gp120 RNA aptamer, inhibits entry of human immunodeficiency virus type 1 subtype C.
    Mufhandu HT; Gray ES; Madiga MC; Tumba N; Alexandre KB; Khoza T; Wibmer CK; Moore PL; Morris L; Khati M
    J Virol; 2012 May; 86(9):4989-99. PubMed ID: 22379083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras.
    McNamara JO; Andrechek ER; Wang Y; Viles KD; Rempel RE; Gilboa E; Sullenger BA; Giangrande PH
    Nat Biotechnol; 2006 Aug; 24(8):1005-15. PubMed ID: 16823371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell-type-specific aptamer and aptamer-small interfering RNA conjugates for targeted human immunodeficiency virus type 1 therapy.
    Zhou J; Rossi J
    J Investig Med; 2014 Oct; 62(7):914-9. PubMed ID: 25118114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cell-specific RNA aptamer against human CCR5 specifically targets HIV-1 susceptible cells and inhibits HIV-1 infectivity.
    Zhou J; Satheesan S; Li H; Weinberg MS; Morris KV; Burnett JC; Rossi JJ
    Chem Biol; 2015 Mar; 22(3):379-90. PubMed ID: 25754473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In Silico Selection of Gp120 ssDNA Aptamer to HIV-1.
    Sepehri Zarandi H; Behbahani M; Mohabatkar H
    SLAS Discov; 2020 Oct; 25(9):1087-1093. PubMed ID: 32452249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.